NEW YORK (GenomeWeb News) – The rate of growth at which drug makers invest in life science tools and technologies may never reach the levels seen during the 2000 or 2001 “boom,” according to Bruker BioSciences CEO Frank Laukien.
 
“It’s certainly better than it has been [recently] but may never again be at the 2000-2001 levels,” Laukien said during a break-out session following his presentation at the UBS Life Sciences Conference here today.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.